BridgeBio Pharma BBIO Cost Of Goods Sold — Cost Of Revenue

Other product segments

Similar metrics at other companies

BIIBProduct revenue, net — Cost of sales, excluding amortization and impairment of acquired intangible assets

$478.7M+3.6%

ILMNProduct revenue — Cost of revenue

$197M-1.7%

KRYSCost of goods sold

$6.32M+25.8%

MRNAProduct Sales, Distribution Fees — Cost of Sales

$0—

BTSGCost Of Goods

$2.87B+23.3%

SCIProduct — Cost of Revenue

$269.22M+3.1%

Questions, answered.

What is BridgeBio Pharma's cost of goods sold — cost of revenue?

BridgeBio Pharma (BBIO) reported cost of goods sold — cost of revenue of $2.85M in Q2 2025.

What does cost of goods sold — cost of revenue mean?

The direct costs incurred to manufacture and supply the company's commercial pharmaceutical products.

How do you interpret cost of goods sold — cost of revenue?

An increase relative to revenue may indicate rising manufacturing costs, supply chain inefficiencies, or a shift in product mix toward lower-margin therapies, while a decrease suggests improved production efficiency or economies of scale.

How does cost of goods sold — cost of revenue compare across companies?

Comparable to cost of revenue metrics in other biopharmaceutical firms, though it may be more volatile for companies in the early stages of commercializing complex gene therapies compared to those with established small-molecule portfolios.